Composition and methods for the treatment of cancer
First Claim
Patent Images
1. An anti-cancer composition comprising:
- a) a cellular energy inhibitor having the structure according to formula I
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I
-
- wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR′, N(R″)2, C(O)R′″, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R′ represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R′″, R″ represents H, C1-C6 alkyl, or C6-C12 aryl, and R′″ represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a glycolysis inhibitor. Further, the anti-cancer composition can comprise a biological buffer that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor.
-
Citations
46 Claims
-
1. An anti-cancer composition comprising:
a) a cellular energy inhibitor having the structure according to formula I - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 22)
- 19. A method of minimizing toxicity of a cellular energy inhibitor of formula (I) to a subject receiving the cellular energy inhibitor comprising, combining in the subject, the cellular energy inhibitor with a biological buffer that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor due to its chemical reaction and/or cellular metabolism:
-
20. A method of minimizing an adverse drug experience associated with administration of an anti-cancer composition to a subject, comprising administering the anti-cancer composition to the subject at a time when the subject'"'"'s blood insulin/glucagon ratio in the range of about 1 to about 10;
- the anti-cancer composition comprising the inhibitor of formula (I);
- View Dependent Claims (23, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)
- the anti-cancer composition comprising the inhibitor of formula (I);
-
21. A method for assessing killing efficacy of an anti-cancer composition in a subject, comprising
a) measuring a lactic acid level in the subject prior to administration of the anti-cancer composition; -
b) administering the anti-cancer composition to the subject; c) measuring the lactic acid level in the subject after administration of the anti-cancer composition; and d) determining the killing efficacy by measuring and/or correlating the difference between the lactic acid levels as a function of treatment time; wherein the anti-cancer composition comprises i) a cellular energy inhibitor having the structure according to formula I - View Dependent Claims (24, 42, 43, 44, 45, 46)
-
Specification